bleomycin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 4742 11056-06-7

Description:

MoleculeDescription

Synonyms:

  • bleomycin
  • bleomycins
  • bleomycin sulfate
  • bleomycin hydrochloride
  • bleomycin HCl
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
  • Molecular weight: 2841.07
  • Formula: C110H168N37O42S5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 688.97
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.43 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.26 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.90 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
July 31, 1973 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 322.50 27.01 191 7386 118258 63363187
Hepatitis B reactivation 215.02 27.01 54 7523 3083 63478362
Neutropenia 210.93 27.01 171 7406 174834 63306611
Pulmonary toxicity 183.76 27.01 61 7516 9394 63472051
Ovarian germ cell teratoma 148.93 27.01 22 7555 56 63481389
Acute hepatic failure 131.23 27.01 57 7520 18270 63463175
Teratoma 126.64 27.01 21 7556 135 63481310
Second primary malignancy 125.87 27.01 44 7533 7909 63473536
Mucosal inflammation 90.47 27.01 61 7516 46867 63434578
Acute myeloid leukaemia 90.10 27.01 43 7534 17104 63464341
Deafness 85.22 27.01 42 7535 17915 63463530
Teratoma benign 82.02 27.01 13 7564 60 63481385
Myelodysplastic syndrome 81.94 27.01 40 7537 16714 63464731
Pancytopenia 78.91 27.01 76 7501 96857 63384588
Bone marrow failure 71.04 27.01 44 7533 29246 63452199
Interstitial lung disease 64.97 27.01 56 7521 61852 63419593
Respiratory failure 64.92 27.01 70 7507 101788 63379657
Cutaneous calcification 61.57 27.01 11 7566 115 63481330
Chloroma 60.34 27.01 12 7565 231 63481214
Febrile bone marrow aplasia 59.75 27.01 25 7552 7300 63474145
Tissue infiltration 59.29 27.01 14 7563 615 63480830
Disease progression 59.11 27.01 73 7504 122685 63358760
Pulmonary fibrosis 58.79 27.01 44 7533 39765 63441680
Basal ganglion degeneration 58.48 27.01 13 7564 435 63481010
Product use in unapproved indication 58.21 27.01 88 7489 178992 63302453
Synovial sarcoma 55.24 27.01 9 7568 51 63481394
Premature baby 55.02 27.01 33 7544 20702 63460743
Respiratory symptom 54.80 27.01 19 7558 3328 63478117
Necrotising gastritis 53.11 27.01 9 7568 67 63481378
Acute respiratory distress syndrome 51.18 27.01 33 7544 23501 63457944
Premature menopause 49.67 27.01 13 7564 873 63480572
Uterine enlargement 49.55 27.01 14 7563 1254 63480191
Drug resistance 49.48 27.01 32 7545 22901 63458544
Thrombocytopenia 44.50 27.01 71 7506 151086 63330359
Foetal exposure during pregnancy 44.25 27.01 34 7543 31928 63449517
Anaemia 43.45 27.01 103 7474 293327 63188118
Inguinal hernia 43.21 27.01 14 7563 1993 63479452
Aplasia 43.20 27.01 17 7560 4242 63477203
Peripheral sensory neuropathy 43.18 27.01 20 7557 7431 63474014
Combined immunodeficiency 42.96 27.01 8 7569 107 63481338
Off label use 42.79 27.01 176 7401 674286 62807159
Anaesthesia 42.67 27.01 10 7567 425 63481020
Primary immunodeficiency syndrome 42.48 27.01 7 7570 43 63481402
Hyperpyrexia 42.19 27.01 16 7561 3616 63477829
Malignant neoplasm progression 41.39 27.01 50 7527 82071 63399374
Psychogenic seizure 41.36 27.01 13 7564 1679 63479766
Sarcoidosis 40.91 27.01 19 7558 7103 63474342
Exposure during pregnancy 40.32 27.01 69 7508 155478 63325967
Lung disorder 40.01 27.01 43 7534 62218 63419227
Leukaemia 39.90 27.01 16 7561 4192 63477253
Flagellate dermatitis 39.34 27.01 8 7569 173 63481272
Cardiotoxicity 37.84 27.01 19 7558 8419 63473026
Pleuroparenchymal fibroelastosis 36.60 27.01 7 7570 109 63481336
Vulvovaginal inflammation 36.15 27.01 10 7567 829 63480616
Pain 36.09 27.01 22 7555 740606 62740839
Septic shock 35.93 27.01 42 7535 66587 63414858
Lymphopenia 35.71 27.01 24 7553 18303 63463142
Neurological decompensation 35.69 27.01 13 7564 2625 63478820
Hypochromic anaemia 35.60 27.01 12 7565 1930 63479515
Dysaesthesia 35.57 27.01 15 7562 4463 63476982
Myelosuppression 34.54 27.01 26 7551 23677 63457768
Rash 34.51 27.01 12 7565 560859 62920586
Traumatic lung injury 33.86 27.01 11 7566 1578 63479867
Tumour lysis syndrome 33.85 27.01 18 7559 8972 63472473
Transdifferentiation of neoplasm 33.77 27.01 5 7572 13 63481432
Haemophagocytic lymphohistiocytosis 33.72 27.01 19 7558 10608 63470837
Monoplegia 33.25 27.01 13 7564 3188 63478257
Haematotoxicity 33.14 27.01 18 7559 9358 63472087
Encephalitis viral 32.93 27.01 11 7566 1721 63479724
Acute promyelocytic leukaemia 30.71 27.01 9 7568 918 63480527
Capillary leak syndrome 30.36 27.01 11 7566 2189 63479256
Pneumocystis jirovecii pneumonia 30.23 27.01 21 7556 16893 63464552
Abdominal compartment syndrome 29.90 27.01 8 7569 585 63480860
Cytopenia 29.57 27.01 18 7559 11583 63469862
Meningitis streptococcal 28.64 27.01 6 7571 151 63481294

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 404.70 22.06 322 9507 136527 34810575
Second primary malignancy 349.90 22.06 117 9712 7769 34939333
Acute myeloid leukaemia 257.62 22.06 118 9711 18152 34928950
Pulmonary toxicity 252.11 22.06 86 9743 6061 34941041
Azoospermia 162.69 22.06 35 9794 406 34946696
Pneumonitis 131.09 22.06 94 9735 33784 34913318
Pulmonary fibrosis 125.65 22.06 73 9756 18323 34928779
Interstitial lung disease 118.57 22.06 117 9712 65165 34881937
Myelodysplastic syndrome 117.53 22.06 71 9758 19137 34927965
Neutropenia 111.24 22.06 175 9654 156603 34790499
Acute respiratory distress syndrome 104.91 22.06 74 9755 25895 34921207
Bone marrow failure 75.69 22.06 64 9765 29189 34917913
Flagellate dermatitis 75.42 22.06 14 9815 70 34947032
Cardiotoxicity 74.89 22.06 35 9794 5613 34941489
Endocarditis noninfective 74.20 22.06 15 9814 125 34946977
Traumatic lung injury 69.21 22.06 22 9807 1238 34945864
Pneumomediastinum 62.74 22.06 24 9805 2343 34944759
Pneumocystis jirovecii pneumonia 61.26 22.06 48 9781 19662 34927440
Papillary thyroid cancer 59.77 22.06 17 9812 652 34946450
Chronic myeloid leukaemia 56.98 22.06 22 9807 2202 34944900
Respiratory failure 55.52 22.06 105 9724 108467 34838635
Pyrexia 53.13 22.06 209 9620 332804 34614298
Cytomegalovirus chorioretinitis 53.09 22.06 24 9805 3565 34943537
Vena cava thrombosis 49.68 22.06 17 9812 1205 34945897
Scleroderma 49.18 22.06 18 9811 1554 34945548
Testicular disorder 48.03 22.06 15 9814 796 34946306
Thrombocytopenia 47.89 22.06 123 9706 156124 34790978
Myositis 47.79 22.06 34 9795 12036 34935066
Pneumothorax 47.79 22.06 41 9788 19051 34928051
Coronary artery thrombosis 47.05 22.06 19 9810 2140 34944962
Lung disorder 46.55 22.06 53 9776 34643 34912459
Leukopenia 44.16 22.06 70 9759 62786 34884316
Off label use 43.56 22.06 232 9597 419292 34527810
Osteonecrosis 43.56 22.06 35 9794 14855 34932247
Malignant neoplasm progression 42.34 22.06 83 9746 87963 34859139
Pulmonary embolism 41.23 22.06 83 9746 89663 34857439
Chloroma 40.91 22.06 12 9817 514 34946588
Teratoma 40.54 22.06 7 9822 21 34947081
Mucosal inflammation 38.83 22.06 51 9778 38571 34908531
Subcutaneous emphysema 38.57 22.06 14 9815 1180 34945922
Autoimmune neutropenia 38.49 22.06 10 9819 271 34946831
Deafness 38.42 22.06 29 9800 11236 34935866
Haematotoxicity 36.94 22.06 25 9804 8169 34938933
Pancytopenia 36.75 22.06 82 9747 95075 34852027
Carotid artery thrombosis 36.18 22.06 10 9819 345 34946757
Blood pressure decreased 35.67 22.06 57 9772 51458 34895644
Taeniasis 35.33 22.06 7 9822 52 34947050
Vascular access site occlusion 35.22 22.06 7 9822 53 34947049
Product use in unapproved indication 34.41 22.06 91 9738 117408 34829694
Acute myocardial infarction 33.89 22.06 57 9772 53662 34893440
Vocal cord inflammation 33.57 22.06 7 9822 69 34947033
Premature ageing 32.62 22.06 7 9822 80 34947022
Cerebral infarction 31.94 22.06 39 9790 27416 34919686
Arterial thrombosis 31.87 22.06 13 9816 1502 34945600
Fall 31.54 22.06 9 9820 202876 34744226
Neutropenic sepsis 31.30 22.06 28 9801 13739 34933363
Ichthyosis 30.92 22.06 7 9822 104 34946998
Lung infiltration 30.85 22.06 27 9802 12878 34934224
Embolism arterial 30.10 22.06 10 9819 647 34946455
Testicular malignant teratoma 30.07 22.06 5 9824 11 34947091
Disease progression 29.92 22.06 82 9747 107995 34839107
Pneumonia salmonella 29.78 22.06 6 9823 49 34947053
Cardiac dysfunction 29.49 22.06 14 9815 2324 34944778
Peripheral artery thrombosis 29.36 22.06 14 9815 2346 34944756
Therapy partial responder 28.96 22.06 23 9806 9593 34937509
Septic shock 28.96 22.06 63 9766 71771 34875331
Osteosarcoma 28.69 22.06 8 9821 285 34946817
Neoplasm progression 28.58 22.06 34 9795 23266 34923836
Dizziness 28.37 22.06 13 9816 218508 34728594
Asthenospermia 28.34 22.06 6 9823 64 34947038
Splenic infarction 27.94 22.06 13 9816 2062 34945040
Febrile bone marrow aplasia 27.70 22.06 21 9808 8188 34938914
Pain 26.84 22.06 12 9817 204663 34742439
Organising pneumonia 26.37 22.06 18 9811 5961 34941141
Rash 26.31 22.06 15 9814 222737 34724365
Death 26.15 22.06 45 9784 398004 34549098
Paternal exposure timing unspecified 25.62 22.06 5 9824 34 34947068
Trisomy 13 25.05 22.06 4 9825 6 34947096
Cerebral venous thrombosis 24.95 22.06 9 9820 745 34946357
Spindle cell sarcoma 24.42 22.06 6 9823 129 34946973
Acute promyelocytic leukaemia 24.40 22.06 8 9821 497 34946605
Fatigue 24.25 22.06 42 9787 370611 34576491
Drug ineffective 24.08 22.06 214 9615 456537 34490565
Sarcoidosis 23.87 22.06 13 9816 2875 34944227
Ischaemic cerebral infarction 23.86 22.06 10 9819 1237 34945865
Arthralgia 23.86 22.06 9 9820 170032 34777070
Guillain-Barre syndrome 23.75 22.06 17 9812 6070 34941032
Blindness 23.75 22.06 25 9804 14961 34932141
Product dose omission issue 23.46 22.06 3 9826 119708 34827394
Respiratory disorder 23.44 22.06 28 9801 19236 34927866
Diaphragm muscle weakness 23.26 22.06 6 9823 158 34946944
Renal salt-wasting syndrome 23.05 22.06 7 9822 338 34946764
Cerebral artery stenosis 22.87 22.06 7 9822 347 34946755
Heart disease congenital 22.82 22.06 10 9819 1380 34945722
Vocal cord paralysis 22.78 22.06 9 9820 957 34946145
Subdural haemorrhage 22.66 22.06 13 9816 3178 34943924
Testicular cancer metastatic 22.17 22.06 5 9824 73 34947029

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 713.92 19.69 485 15241 230514 79498148
Second primary malignancy 449.08 19.69 150 15576 14200 79714462
Pulmonary toxicity 368.62 19.69 126 15600 12788 79715874
Acute myeloid leukaemia 359.99 19.69 157 15569 30728 79697934
Neutropenia 292.52 19.69 320 15406 287390 79441272
Myelodysplastic syndrome 205.13 19.69 106 15620 30195 79698467
Interstitial lung disease 184.77 19.69 163 15563 112437 79616225
Pulmonary fibrosis 160.55 19.69 103 15623 44009 79684653
Acute respiratory distress syndrome 155.71 19.69 101 15625 43966 79684696
Pneumonitis 150.47 19.69 112 15614 60748 79667914
Teratoma 147.36 19.69 26 15700 142 79728520
Ovarian germ cell teratoma 137.87 19.69 22 15704 56 79728606
Bone marrow failure 128.44 19.69 95 15631 51012 79677650
Pancytopenia 119.42 19.69 155 15571 165590 79563072
Pneumocystis jirovecii pneumonia 113.57 19.69 74 15652 32434 79696228
Respiratory failure 113.28 19.69 158 15568 180753 79547909
Thrombocytopenia 110.59 19.69 192 15534 265067 79463595
Flagellate dermatitis 110.35 19.69 22 15704 251 79728411
Mucosal inflammation 105.49 19.69 100 15626 75480 79653182
Malignant neoplasm progression 102.36 19.69 130 15596 135860 79592802
Teratoma benign 101.52 19.69 17 15709 64 79728598
Peripheral sensory neuropathy 89.33 19.69 46 15680 12987 79715675
Chloroma 87.64 19.69 22 15704 748 79727914
Traumatic lung injury 86.85 19.69 28 15698 2363 79726299
Haematotoxicity 84.51 19.69 47 15679 15472 79713190
Pneumomediastinum 82.51 19.69 30 15696 3637 79725025
Lung disorder 82.15 19.69 90 15636 80467 79648195
Chronic myeloid leukaemia 78.82 19.69 29 15697 3635 79725027
Disease progression 77.46 19.69 134 15592 184228 79544434
Cardiotoxicity 74.77 19.69 40 15686 12199 79716463
Product use in unapproved indication 74.37 19.69 157 15569 250202 79478460
Endocarditis noninfective 72.01 19.69 15 15711 216 79728446
Pyrexia 69.64 19.69 291 15435 678418 79050244
Pain 64.77 19.69 29 15697 703773 79024889
Pneumothorax 63.06 19.69 49 15677 28274 79700388
Sarcoidosis 61.72 19.69 31 15695 8304 79720358
Off label use 59.36 19.69 342 15384 906873 78821789
Febrile bone marrow aplasia 59.03 19.69 35 15691 12985 79715677
Myelitis 55.43 19.69 20 15706 2371 79726291
Cutaneous calcification 54.59 19.69 11 15715 133 79728529
Rash 54.49 19.69 23 15703 578335 79150327
Therapy partial responder 54.46 19.69 37 15689 17360 79711302
Necrotising gastritis 54.05 19.69 10 15716 74 79728588
Pleuroparenchymal fibroelastosis 53.78 19.69 11 15715 144 79728518
Acute promyelocytic leukaemia 52.28 19.69 17 15709 1474 79727188
Leukopenia 50.61 19.69 86 15640 116427 79612235
Subcutaneous emphysema 49.19 19.69 17 15709 1777 79726885
Osteonecrosis 48.89 19.69 44 15682 31051 79697611
Septic shock 48.60 19.69 87 15639 122714 79605948
Azoospermia 47.32 19.69 10 15716 155 79728507
Synovial sarcoma 46.98 19.69 9 15717 82 79728580
Stem cell transplant 46.94 19.69 20 15706 3684 79724978
Coronary artery thrombosis 46.88 19.69 19 15707 3087 79725575
Papillary thyroid cancer 46.67 19.69 18 15708 2568 79726094
Deafness 45.97 19.69 36 15690 21001 79707661
Myositis 44.49 19.69 34 15692 19134 79709528
Cytomegalovirus chorioretinitis 42.36 19.69 21 15705 5469 79723193
Basal ganglion degeneration 42.16 19.69 11 15715 437 79728225
Tissue infiltration 41.88 19.69 12 15714 679 79727983
Cytopenia 40.52 19.69 33 15693 20350 79708312
Tumour lysis syndrome 39.87 19.69 35 15691 23904 79704758
Joint swelling 39.85 19.69 5 15721 288641 79440021
Myelosuppression 39.29 19.69 44 15682 40252 79688410
Combined immunodeficiency 39.16 19.69 8 15718 104 79728558
Peripheral swelling 38.90 19.69 4 15722 269613 79459049
Uterine enlargement 38.64 19.69 12 15714 896 79727766
Haemophagocytic lymphohistiocytosis 38.53 19.69 33 15693 21804 79706858
Acute lymphocytic leukaemia 38.32 19.69 19 15707 4950 79723712
Weight increased 37.82 19.69 5 15721 277381 79451281
Taeniasis 37.81 19.69 7 15719 52 79728610
Product dose omission issue 37.51 19.69 3 15723 247534 79481128
Anaemia 37.34 19.69 180 15546 444835 79283827
Scleroderma 36.46 19.69 19 15707 5491 79723171
Tooth malformation 36.42 19.69 8 15718 150 79728512
Fall 36.31 19.69 26 15700 487603 79241059
Primary immunodeficiency syndrome 36.04 19.69 7 15719 69 79728593
Vulvovaginal inflammation 35.42 19.69 10 15716 536 79728126
Lung infiltration 35.19 19.69 32 15694 22880 79705782
Vascular access site occlusion 35.18 19.69 7 15719 79 79728583
Leukaemia 35.17 19.69 19 15707 5906 79722756
Diarrhoea 35.15 19.69 76 15650 880413 78848249
Cerebral infarction 34.84 19.69 44 15682 45632 79683030
Premature ageing 34.63 19.69 7 15719 86 79728576
Vena cava thrombosis 34.61 19.69 15 15711 2880 79725782
Autoimmune neutropenia 34.47 19.69 10 15716 591 79728071
Pulmonary embolism 33.94 19.69 92 15634 171562 79557100
Acute myocardial infarction 33.62 19.69 57 15669 76979 79651683
Aplasia 32.80 19.69 20 15706 7800 79720862
Asthenospermia 32.60 19.69 6 15720 43 79728619
Arthralgia 32.53 19.69 39 15687 571764 79156898
Cerebral venous thrombosis 32.05 19.69 14 15712 2739 79725923
Hepatitis B reactivation 31.89 19.69 18 15708 6090 79722572
Testicular malignant teratoma 31.85 19.69 5 15721 11 79728651
Organising pneumonia 31.26 19.69 22 15704 10917 79717745
Anaesthesia 31.26 19.69 9 15717 518 79728144
Pneumonia salmonella 30.91 19.69 6 15720 59 79728603
Ichthyosis 30.72 19.69 7 15719 156 79728506
Anxiety 30.47 19.69 6 15720 248506 79480156
Psychogenic seizure 29.79 19.69 12 15714 1919 79726743
Hodgkin's disease recurrent 29.42 19.69 5 15721 21 79728641
Swelling 29.31 19.69 4 15722 216707 79511955
Hyperpyrexia 29.26 19.69 17 15709 6075 79722587
Respiratory disorder 29.23 19.69 40 15686 44816 79683846
Arterial thrombosis 29.20 19.69 13 15713 2661 79726001
Neoplasm progression 29.13 19.69 43 15683 51639 79677023
Brain oedema 28.86 19.69 30 15696 25233 79703429
Abdominal discomfort 28.82 19.69 7 15719 250720 79477942
Bacterial infection 28.53 19.69 33 15693 31247 79697415
Sinusitis 27.93 19.69 3 15723 195498 79533164
Guillain-Barre syndrome 27.90 19.69 19 15707 8946 79719716
Dizziness 27.76 19.69 38 15688 526403 79202259
Peripheral sensorimotor neuropathy 27.72 19.69 13 15713 2997 79725665
Lymphopenia 27.48 19.69 32 15694 30525 79698137
Nasopharyngitis 27.45 19.69 8 15718 253873 79474789
Vocal cord inflammation 27.42 19.69 7 15719 255 79728407
Blood pressure decreased 26.75 19.69 60 15666 99406 79629256
Ototoxicity 26.68 19.69 13 15713 3261 79725401
Encephalitis viral 26.45 19.69 12 15714 2567 79726095
Blood pressure increased 26.12 19.69 5 15721 211355 79517307
Left ventricular dysfunction 25.81 19.69 25 15701 19336 79709326
Embolism arterial 25.39 19.69 10 15716 1508 79727154
Splenic infarction 25.30 19.69 13 15713 3651 79725011
Death 25.04 19.69 46 15680 566468 79162194
Infusion site joint movement impairment 24.58 19.69 4 15722 12 79728650
Renal salt-wasting syndrome 24.44 19.69 8 15718 708 79727954
Testicular cancer metastatic 24.41 19.69 5 15721 66 79728596
Diaphragm muscle weakness 24.40 19.69 6 15720 187 79728475
Monoplegia 24.31 19.69 13 15713 3958 79724704
Fatigue 24.19 19.69 98 15628 929629 78799033
B precursor type acute leukaemia 24.01 19.69 7 15719 421 79728241
Pruritus 23.41 19.69 26 15700 394622 79334040
Congestive cardiomyopathy 23.26 19.69 19 15707 11761 79716901
Spindle cell sarcoma 23.25 19.69 6 15720 228 79728434
Lung diffusion test decreased 23.22 19.69 9 15717 1301 79727361
Peripheral artery thrombosis 23.02 19.69 12 15714 3471 79725191
Neurotoxicity 22.72 19.69 30 15696 32488 79696174
Lymphadenopathy 22.70 19.69 39 15687 53208 79675454
Urinary tract infection 22.64 19.69 13 15713 274499 79454163
Insomnia 22.64 19.69 10 15716 245160 79483502
Oropharyngeal squamous cell carcinoma 22.49 19.69 6 15720 260 79728402
Transdifferentiation of neoplasm 22.32 19.69 5 15721 103 79728559
Hodgkin's disease nodular sclerosis 22.21 19.69 4 15722 25 79728637
Dysaesthesia 22.11 19.69 14 15712 5834 79722828
Subdural haemorrhage 21.89 19.69 14 15712 5934 79722728
Infusion related reaction 21.88 19.69 9 15717 230228 79498434
Muscle spasms 21.87 19.69 4 15722 174726 79553936
Hypothyroidism 21.85 19.69 38 15688 52354 79676308
Carotid artery thrombosis 21.56 19.69 11 15715 3042 79725620
Abdominal compartment syndrome 21.49 19.69 9 15717 1588 79727074
Neuropathy peripheral 21.48 19.69 69 15657 141236 79587426
Infusion site ulcer 21.46 19.69 4 15722 31 79728631
Overdose 21.44 19.69 5 15721 184201 79544461
Venoocclusive liver disease 21.20 19.69 18 15708 11753 79716909
Deep vein thrombosis 21.14 19.69 62 15664 120857 79607805
Infusion site hypoaesthesia 20.92 19.69 4 15722 36 79728626
Invasive lobular breast carcinoma 20.52 19.69 7 15719 704 79727958
Ischaemic cerebral infarction 20.46 19.69 10 15716 2525 79726137
Klebsiella infection 20.40 19.69 20 15706 15700 79712962
Osteosarcoma 20.25 19.69 6 15720 382 79728280
Cerebral artery stenosis 20.01 19.69 7 15719 758 79727904
Musculoskeletal stiffness 19.88 19.69 5 15721 175003 79553659
Chills 19.78 19.69 73 15653 160161 79568501
Hypochromic anaemia 19.69 19.69 10 15716 2741 79725921

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35610 antineoplastic agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000180854 Cytoprotective Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diffuse non-Hodgkin's lymphoma, large cell indication 109969005
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Malignant tumor of head and/or neck indication 255056009
Follicular non-Hodgkin's lymphoma indication 308121000
Malignant tumor of cervix indication 363354003 DOID:4362
Malignant tumor of penis indication 363516004 DOID:11615
International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma indication 385370007
Squamous cell carcinoma indication 402815007 DOID:1749
Pleural Malignant Effusions indication
Testicular Germ Cell Tumor indication
Mycosis fungoides off-label use 118618005
Ovarian Germ Cell Tumor Carcinoma off-label use




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aspartyl/asparaginyl beta-hydroxylase Enzyme IC50 5.83 CHEMBL

External reference:

IDSource
D02177 KEGG_DRUG
4019637 VUID
N0000147730 NUI
9041-93-4 SECONDARY_CAS_RN
4018135 VANDF
4019637 VANDF
CHEBI:3139 CHEBI
CHEMBL403664 ChEMBL_ID
2721 INN_ID
67763-87-5 SECONDARY_CAS_RN
DB00290 DRUGBANK_ID
40S1VHN69B UNII
1621 RXNORM
4293 MMSL
9784 MMSL
d00177 MMSL
002661 NDDF
004820 NDDF
009872 NDDF
15660006 SNOMEDCT_US
372843005 SNOMEDCT_US
703085003 SNOMEDCT_US
76591000 SNOMEDCT_US
C0005740 UMLSCUI
D001761 MESH_DESCRIPTOR_UI
CHEMBL3085504 ChEMBL_ID
5360373 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9240 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9240 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9241 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9241 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-3154 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 19 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-3155 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 19 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-886 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-908 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-136 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-137 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 69097-364 INJECTION 15 [USPU] INTRAMUSCULAR ANDA 20 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 70121-1567 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15000 [iU] INTRA-ARTERIAL UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 18 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 70121-1567 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15000 [iU] INTRA-ARTERIAL UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 18 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-106 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 24 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-107 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 24 sections